Juno Therapeutics, Inc.
JUNO
JUNO was delisted on the 5th of March, 2018.
0 hedge funds and large institutions have $0 invested in Juno Therapeutics, Inc. in 2018 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
100% less funds holding
Funds holding: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $166K → $0 (-$166K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IA
IFP Advisors
Tampa,
Florida
|
-$159K |
| 2 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$7K |
JUNO Hedge Fund Activity: Q2 2018 in Review
0 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Juno Therapeutics, Inc. (JUNO) for Q2 2018, worth a combined $0 — down 100% from $166K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of JUNO and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was IFP Advisors, exiting entirely with an estimated $159K sold.
- 0 institutional investors held Juno Therapeutics, Inc. (JUNO) as of Q2 2018, down from 2 in Q1 2018.
- Funds reported $0 of Juno Therapeutics, Inc. stock for Q2 2018, down 100% quarter-over-quarter.
- 0 funds opened new Juno Therapeutics, Inc. positions in Q2 2018 and 2 closed out, a net change of -2 holders.
- The largest Juno Therapeutics, Inc. seller in Q2 2018 was IFP Advisors, an estimated $159K sold.
Based on aggregated 13F filings for Q2 2018.